Apoptosis induction by arsenic: Mechanisms of action and possible clinical applications for treating therapy-resistant cancers

Drug Resistance Updates

Volumn 3, Issue 1, 2000, Pages 21-29

  Bode, Ann ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; MELARSONYL POTASSIUM; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; CANCER RESISTANCE; CELL PROLIFERATION; DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; TRANSCRIPTION REGULATION;

EID: 0034143594     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0114     Document Type: Article

References (80)

1. Goering P. L., Aposhian H. V., Mass M. J., Cebrian M., Beck B. D., Waalkes M. P. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci. 49:1999;5-14.
2. Hartwig A. Carcinogenicity of metal compounds: possible role of DNA repair inhibition. Toxicol Lett. 102-103:1998;235-239.
3. Soignet S. L., Maslak P., Wang Z. G. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 339:1998;1341-1348.
4. Bergstrom S. K., Gillan E., Quinn J. J., Altman A. J. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report. J Pediatr Hematol Oncol. 20:1998;545-547.
5. 3induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1996;1052-1061.
6. Kitamura K., Kiyoi H., Yoshida H. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer Chemother Pharmacol. 40:1997;S36-S41.
7. Galimberti S., Papineschi F., Carmignani A., Testi R., Fazzi R., Petrini M. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplant. 24:1999;345-348.
8. Konig A., Wrazel L., Warrell R. P. Jr. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood. 90:1997;562-570.
9. 3exerts dose-dependent dual effects on APL cells. Blood. 89:1997;3345-3353.
10. Agis H., Weltermann A., Mitterbauer G. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Ann Hematol. 78:1999;329-332.
11. Estrov Z., Manna S. K., Harris D. Phenylarsine oxide blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappa B, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 94:1999;2844-2853.
12. Rousselot P., Labaume S., Marolleau J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 59:1999;1041-1048.
13. Zhu X. H., Shen Y. L., Jing Y. K. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 91:1999;772-778.
14. Huff J., Waalkes M., Nyska A., Chan P. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 91:1999;1690-1691.
15. Hayes R. B. The carcinogenicity of metals in humans. Cancer Causes Control. 8:1997;371-385.
16. Abernathy Co, Liu Y. P., Longfellow D. Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect. 107:1999;593-597.
17. Ma D. C., Sun Y. H., Chang K. Z. Selective induction of apoptosis of NB4 cells from G2+M phase by sodium arsenite at lower doses. Eur J Haematol. 61:1998;27-35.
18. Zheng J., Deng Y. P., Lin C., Fu M., Xiao P. G., Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer. 82:1999;286-292.
19. Lu M., Levin J., Sulpice E. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol. 27:1999;845-852.
20. Shen Z. Y., Tan L. J., Cai W. J. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med. 4:1999;33-37.
21. Huang C., Ma W. Y., Li J., Goranson A., Dong Z. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem. 274:1999;14595-14601.
22. Huang C., Ma W. Y., Li J., Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 59:1999;3053-3058.
23. Ludwig S., Hoffmeyer A., Goebeler M. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem. 273:1998;1917-1922.
24. Huang C., Ma W. Y., Li J., Hecht S. S., Dong Z. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis. Cancer Res. 58:1998;4102-4106.
25. Shao W., Fanelli M., Ferrara F. F. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 90:1998;124-133.
26. Wang J. X., Saunthararajah Y., Redner R. L., Liu J. M. Inhibition of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 59:1999;2766-2769.
27. Elbirt K. K., Whitmarsh A. J., Davis R. J., Bonkovsky H. L. Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases [published erratum appears in J Biol Chem 1998 Jul 10; 273(28): 179]. J Biol Chem. 273:1998;8922-8931.
28. Wiegant F. A., Spieker N., van Wijk R. Stressor-specific enhancement of hsp induction by low doses of stressors in conditions of self- and cross-sensitization. Toxicology. 127:1998;107-119.
29. Wiegant F. A., Souren J. E., van Wijk R. Stimulation of survival capacity in heat shocked cells by subsequent exposure to minute amounts of chemical stressors; role of similarity in hsp-inducing effects. Hum Exp Toxicol. 18:1999;460-470.
30. DeMeester S. L., Buchman T. G., Qiu Y. Heat shock induces IkappaB-alpha and prevents stress-induced endothelial cell apoptosis. Arch Surg. 132:1997;1283-1288.
31. Kim S. H., Yeo G. S., Lim Y. S., Kang C. D., Kim C. M., Chung B. S. Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med. 30:1998;87-92.
32. Swank G. M., Lu Q., Xu D. Z., Michalsky M., Deitch E. A. Effect of acute-phase and heat-shock stress on apoptosis in intestinal epithelial cells (Caco-2). Crit Care Med. 26:1998;1213-1217.
33. Bazarbachi A., El-Sabban M. E., Nasr R. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 93:1999;278-283.
34. Lallemand-Breitenbach V., Guillemin M. C., Janin A. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 189:1999;1043-1052.
35. Gianni M., Koken M. H., Chelbi-Alix M. K. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 91:1998;4300-4310.
36. Amundson S. A., Myers T. G., Fornace A. J. Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 17:1998;3287-3299.
37. Merritt A. J., Potten C. S., Kemp C. J. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res. 54:1994;614-617.
38. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
39. Salazar A. M., Ostrosky-Wegman P., Menendez D., Miranda E., Garcia-Carranca A., Rojas E. Induction of p53 protein expression by sodium arsenite. Mutat Res. 381:1997;259-265.
40. Hamadeh H. K., Vargas M., Lee E., Menzel D. B. Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. Biochem Biophys Res Commun. 263:1999;446-449.
41. Harvey M., Sands A. T., Weiss R. S. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 8:1993;2457-2467.
42. Cavigelli M., Li W. W., Lin A., Su B., Yoshioka K., Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. Embo J. 15:1996;6269-6279.
43. Huang C., Ma W. Y., Ryan C. A., Dong Z. Proteinase inhibitors I and II from potatoes specifically block UV - induced activator protein-1 activation through a pathway that is independent of extracellular signal-regulated kinases, c-Jun N-terminal kinases, and P38 kinase. Proc Natl Acad Sci U S A. 94:1997;11957-11962.
44. Huang C., Ma W. Y., Dawson M. I., Rincon M., Flavell R. A., Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA. 94:1997;5826-5830.
45. Huang C., Ma W. Y., Young M. R., Colburn N., Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci U S A. 95:1998;156-161.
46. Oh-hashi K., Maruyama W., Yi H., Takahashi T., Naoi M., Isobe K. Mitogen-activated protein kinase pathway mediates peroxynitrite-induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun. 263:1999;504-509.
47. Nishio K., Fukuoka K., Fukumoto H. Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells. Int J Oncol. 14:1999;461-469.
48. Encinas M., Iglesias M., Llecha N., Comella J. X. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem. 73:1999;1409-1421.
49. Reardon D. B., Contessa J. N., Mikkelsen R. B. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene. 18:1999;4756-4766.
50. Li Y. M., Broome J. D. Apoptosis induced in premyelocytic leukemia cells by arsenic and proteasome inhibitors. Blood. 90:1997;202b.
51. Li Y. M., Broome J. D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 59:1999;776-780.
52. Basu S., Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene. 17:1998;3277-3285.
53. Meriin A. B., Yaglom J. A., Gabai V. L. Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72 [published erratum appears in Mol Cell Biol 1999 Jul; 19(7):5235]. Mol Cell Biol. 19:1999;2547-2555.
54. Chen N. Y., Ma W. Y., Yang C. S., Dong Z. Inhibition of arsenite-induced apoptosis and AP-1 activity by EGCG and theaflavins. J Environmental Pathology, Toxicology, and Oncology. 1999.
55. Chen N. Y., Ma W. Y., Huang C., Ding M., Dong Z. Activation of PKC is required for arsenate-induced signal transduction. J Environmental Pathology, Toxicology, and Oncology. 1999.
56. Newton A. C. Protein kinase C. Seeing two domains. Curr Biol. 5:1995;973-976.
57. Huang X. J., Wiernik P. H., Klein R. S., Gallagher R. E. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol. 16:1999;58-64.
58. Liu Y., Guyton K. Z., Gorospe M., Xu Q., Lee J. C., Holbrook N. J. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic Biol Med. 21:1996;771-781.
59. Akao Y., Nakagawa Y., Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 455:1999;59-62.
60. Dai J., Weinberg R. S., Waxman S., Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 93:1999;268-277.
61. Shimizu M., Hochadel J. F., Fulmer B. A., Waalkes M. P. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol Sci. 45:1998;204-211.
62. Scott N., Hatlelid K. M., MacKenzie N. E., Carter D. E. Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem Res Toxicol. 6:1993;102-106.
63. Rappa G., Lorico A., Flavell R. A., Sartorelli A. C. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 57:1997;5232-5237.
64. Iordanov M. S., Magun B. E. Different mechanisms of c-Jun NH2-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors. J Biol Chem. 274:1999;25801-25806.
65. Jing Y., Dai J., Chalmers-Redman R. M., Tatton W. G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway [In Process Citation]. Blood. 94:1999;2102-2111.
66. Chen Y. C., Lin-Shiau S. Y., Lin J. K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol. 177:1998;324-333.
67. Gurr J. R., Bau D. T., Liu F., Lynn S., Jan K. Y. Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells. Mol Pharmacol. 56:1999;102-109.
68. Lynn S., Shiung J. N., Gurr J. R., Jan K. Y. Arsenite stimulates poly(ADP-ribosylation) by generation of nitric oxide. Free Radic Biol Med. 24:1998;442-449.
69. Shumilla J. A., Wetterhahn K. E., Barchowsky A. Inhibition of NF-kappa B binding to DNA by chromium, cadmium, mercury, zinc, and arsenite in vitro: evidence of a thiol mechanism. Arch Biochem Biophys. 349:1998;356-362.
70. Wesselborg S., Bauer M. K. A., Vogt M., Schmitz M. L., Schulze-Osthoff K. Activation of transcription factor NFkB and p38 mitogen-activated protein kinase is mediated by distinct and separate stress effector pathways. J Biol Chem. 272:1997;12422-12429.
71. Alpert D., Schwenger P., Han J., Vilcek J. Cell stress and MKK6b-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced IkappaB phosphorylation and NF-kappaB activation. J Biol Chem. 274:1999;22176-22183.
72. Barchowsky A., Dudek E. J., Treadwell M. D., Wetterhahn K. E. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 21:1996;783-790.
73. Kaltreider R. C., Pesce C. A., Ihnat M. A., Lariviere J. P., Hamilton J. W. Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding. Mol Carcinog. 25:1999;219-229.
74. Green D. R., Reed J. C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
75. Kroemer G., Dallaporta B., Resche R. M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 60:1998;619-642.
76. Kroemer G., de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst. 91:1999;743-745.
77. Larochette N., Decaudin D., Jacotot E. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res. 249:1999;413-421.
78. Decaudin D., Marzo I., Brenner C., Kroemer G. Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy. Int J Oncol. 12:1998;141-152.
79. Marzo I., Brenner C., Kroemer G. The central role of the mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondria, and purified protein complexes. Biomed Pharmacother. 52:1998;248-251.
80. Marzo I., Brenner C., Zamzami N. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med. 187:1998;1261-1271.